ELI LILLY & Co
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $65.2 | $45.0 | $34.1 | $28.5 | $28.3 |
| Net income | $20.6 | $10.6 | $5.2 | $6.2 | $5.6 |
| Balance Sheet | |||||
| Total debt | $42.5 | $33.6 | $25.2 | $16.2 | $16.9 |
| Cash Flow Statement | |||||
| Free cash flow | $9.0 | $3.8 | $0.8 | $5.7 | $6.1 |
| Dividends | $5.4 | $4.7 | $4.1 | $3.5 | $3.1 |
| Share repurchases | $4.1 | $2.5 | $0.8 | $1.5 | $1.2 |
Shares outstanding 941.4M · Free float 90.1%
Annual filing data through FY ended December 31, 2025; float as of September 14, 2026.
Coverage
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
September 23, 2026
Drug Pipeline
Abivax, Merck and Teva–Sanofi pursue the next wave of colitis therapies
September 23, 2026
Drug Pipeline
Lilly’s Zepbound sets an approved benchmark for dual-agonist obesity drugs
September 23, 2026
Drug Pipeline
Lilly’s triple agonist retatrutide heads toward a planned US filing
September 23, 2026
Drug Pipeline
Lilly’s Foundayo brings oral GLP-1 treatment into the obesity market
September 23, 2026
Drug Pipeline
Lilly and Novo set the backdrop for a changing obesity pipeline
September 23, 2026
Drug Pipeline
Lilly’s Omvoh follows induction with maintenance in ulcerative colitis